GSK stock: buy or sell?

GSK stock price: $47.89 1.55% At close on January 17th, 2020

Updated on:
January 17th, 2020


GlaxoSmithKline raised 1.55% yesterday and set a new all time high at $48.22.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide.

Should I buy GSK stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to define your own trading strategy that fits your character as inversor. At, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, 2 buy setups match with GlaxoSmithKline stock right now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is GlaxoSmithKline stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we detected 15 ratings published for GSK stock in the last month.

Is GSK a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-30Shore Capitaln/aHold
2019-9-30Jefferies Financial Groupn/aBuy
2019-9-30Deutsche Bankn/aHold
2019-9-3Societe GeneraleSellBuy
2019-9-27UBS Groupn/aNeutral
2019-9-27JPMorgan Chase & Co.n/aNeutral
2019-9-27Goldman Sachs Groupn/aBuy
2019-9-20JPMorgan Chase & Co.n/aNeutral
2019-9-2Deutsche Bankn/aHold
2019-9-13Barclaysn/aEqual weight
2019-9-13Bank of American/aNeutral
2019-8-29Jefferies Financial Groupn/aBuy

GSK stock analysis

Daily outlook

After several days of continuous hikes in past weeks, GlaxoSmithKline raised 1.55% to $47.89.

Shares of GlaxoSmithKline closed yesterday at $47.89 after reaching a new all time high ($48.22) and raised a beatiful 1.55%. On September GSK price bounced up over the SMA of 50 days demonstrating to be a significant support for this stock.

GSK stock chart (daily)

Weekly outlook

GlaxoSmithKline closed this week at $47.89 after reaching a new all time high ($48.22) and jumped a fine 2.35%.

GSK shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom last week, GSK climbed unceasignly breaking out to new all time highs. Since price and SMA40w lines crossed up early June, GSK climbed $10.12 (26.79%). By mid March 2019, SMA20w and SMA40w crossed up triggering a rise of 22.04%.

GSK stock chart (weekly)

GSK stock price history

GSK IPO was on March 28th, 1980 at $0.00 per share1. Since then, GSK stock grew a inf%, with an average of inf% per year. If you had invested right after GSK's IPO a $1,000 in GSK stock in 1980, it would worth $inf today.

1: Adjusted price after possible price splits or reverse-splits.

GSK stock historical price chart

GSK stock reached all-time highs yesterday with a price of $48.22.

GSK stock price target

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' GSK stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price prediction for GlaxoSmithKline stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, GlaxoSmithKline presented its financial report, posting a great gain for the Earnings per Share (EPS) ratio. Experts were expecting $0.70 per share, but GlaxoSmithKline posted $0.79.
GSK earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual revenues report draw a tiny increase of 2.10% to $30,821.00 M dollars. When comparing 2018 vs 2017, in line, profit margin (that is, the net income divided by revenues) rose a 6.68% to 11.75%.

GSK annual Sales and Income evolution
2013$26,510 M-$5,440 M20.5%-
2014$35,840 M35.19%$4,293 M12.0%-21.08%
2015$23,923 M-33.25%$8,422 M35.2%96.16%
2016$27,889 M16.58%$912 M3.3%-89.17%
2017$30,186 M8.24%$1,532 M5.1%67.98%
2018$30,821 M2.10%$3,623 M11.8%136.49%

Quarterly financial results

GlaxoSmithKline reported $8,197.00 million in sales for 2018-Q4, a 1.30% improvement compared to previous quarter. Reported quarter earnings marked $1,215.00 million with a profit margin of 14.82%. Profit margin depreciated a -2.70% compared to previous quarter when profit margin was 17.52%. When comparing turnover to same quarter last year, GlaxoSmithKline sales marked a frightening loss and plunged a -20.59%. Looking back to recent quarterly results, GlaxoSmithKline posted 3 negative quarters in a row.
GSK quarterly Sales and Income evolution
2017-Q2$7,320 M-$-180 M-2.5%-
2017-Q3$10,507 M43.54%$1,624 M15.5%-1,002.02%
2017-Q4$10,323 M-1.75%$-738 M-7.1%-145.44%
2018-Q1$7,222 M-30.04%$549 M7.6%-174.41%
2018-Q2$7,310 M1.22%$441 M6.0%-19.67%
2018-Q3$8,092 M10.70%$1,418 M17.5%221.54%
2018-Q4$8,197 M1.30%$1,215 M14.8%-14.32%
2019-Q1$7,661 M-6.54%$830 M10.8%-31.69%

GlaxoSmithKline ownership

When you are planning to buy a stock, it's always worth to overview its ownership structure.

GlaxoSmithKline shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.01% of all shares.

In case of GlaxoSmithKline stock, 11.66% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for GSK stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to GlaxoSmithKline:

Market cap$119.2 B
Total shares2,490.0 M
Float shares2,450.0 M
  - Institutional holdings (%)11.7%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

GSK summary

Friday, January 17th, 2020
Day range$47.80 - $48.22
Previous close$47.16
Session gain1.55%
Average true range$0.48
50d mov avg$45.74
100d mov avg$43.82
200d mov avg$41.61
Daily pattern
Weekly pattern lb03c

GlaxoSmithKline performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared GlaxoSmithKline against in the following table:

GlaxoSmithKline competitors

Unfortunately, we could not find any public company that could be defined as GlaxoSmithKline competitor. This doesn't mean GlaxoSmithKline does not have any competitor in the market, it's just we could not detected it.

    Latest GSK stock news